| CEO Name | Alexander Hardy |
| Nationality | United Kingdom |
| Net Worth Estimation | $30 million |
Alexander Hardy's estimated net worth of around $30 million primarily results from his executive compensation, stock awards, and performance bonuses accrued during his tenure as CEO of Genentech and Roche Pharmaceuticals. Additional wealth stems from long-term stock option grants, company incentives, and profit-sharing linked to Genentech's steady revenue growth within the biotechnology sector.
Alexander Hardy, CEO of Genentech, has an estimated net worth of $30,000,000, which is 28.6% of the maximum and 300% of the minimum net worth in the Biotechnology sector. His net worth places him solidly within the estimated range for CEOs in this business category.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Alexander Hardy Performance in Genentech
Alexander Hardy, CEO of Genentech, demonstrates strategic leadership by driving innovation and aligning teams towards cutting-edge biotech solutions. His decision-making emphasizes data-driven approaches and collaborative partnerships, accelerating drug development pipelines. Under Hardy's leadership, Genentech has enhanced operational performance, expanded its therapeutic portfolio, and strengthened its position as a pioneer in personalized medicine.
Latest News
Genentech Breaks Ground on $700 Million Manufacturing Facility in North Carolina
Genentech, led by CEO Ashley Magargee, announced a major expansion with a new $700 million facility in Holly Springs, NC, creating over 1,900 jobs and supporting next-generation metabolic medicines, including obesity treatments. The project is part of Roche's $50 billion U.S. investment in manufacturing, infrastructure, and R&D.
Source: http://www.businesswire.com/news/home/20250825778031/en/Genentech-and-Roche-Break-Ground-on-State-of-the-Art-Manufacturing-Facility-in-Holly-Springs-North-Carolina